Combination Therapy with Interferon and Ofloxacin


 What is Hepatitis

 How is it Transmitted

 Long Term Prognosis

 Complications of HCV

 Liver Biopsy

 Treatment Info (Interferon, Herbal, etc)

 Lab Tests (PCR, Genotype,etc.)

 Nutrition & Alternative Info

 Patient Information (Support Groups, Doctor Listing, etc)

 Related Webpages

 Transplant Info

 Site Search

 HCV Webrings

 My guestbookbook

 Site Awards

 FAQ & Disclaimers

"Effect of a combination therapy with interferon and ofloxacin for chronic type-C hepatitis: A Multicenter Randomized Trail"
A. Takada, M. Tsutsumi and M. Sawada, Div. of Gastroenterology., Dept of INt. Med., Kanazawa Med. University., Uchinada, Ishikawa, 920-02 Japan

Interferon (IFN) is effective in only a limited number of patients iwth the 1b type of hepatitis C virus (HCV) indicating that a combination therapy with other antiviral drugs may be essential to obtain betterr results. We have reported that an antibacterial drug, ofloxacin (OFLX) may be effective for HCV infection. In the present study, the effects of a combination therapy with IFN and OFLX were analyzed by a multicenter randomized trial. Over 6 million units of various types o fIFN with 600 mg of OFLX per day were given to 62 patients with a chronic type C hepatitis in 8 different hospitals. The schedule of the combinatio therapy was categorized into 3 types. In 33 patients who have no IFN therapy previously, IFN was given daily for 2-3 weeks and then 3 times for 21-22 weeks. OFLX was given for 12 weeks from the 8th week of IFN treatment (regular group I). In 10 patients who did not respond well to IFN alone treatment for more than 12 weeks, OFLX was given with IFN for more than 12 weeks (additional treatment, group II). In 14 patients who were non-responders to IFN alone treatment for 24 weeks, combination therapy was conducted in the same schedule for group I (re-treatment, group III). In group I, 16 out of 25 patients with HCV-1b were responders who continued normal AST levels for 6 months after ceasing treatment. Eight patients with other HCV subtypes, were all responders. In group II, responder was found in 5 out 8 patients with HCV-1b and 1 out of 2 patients with other subtypes. In group III, responders were found in 4 out of 9 patients with HCV-1b and in all four patienst with other subtypes. The incidence of responders was higher than in previously reported valued with IFN-alone treatment. Severe side effect was found only 2 patients. These results suggest that a combination therapy with IFN and OFLX is an effective treatmetn for chronic type C hepatitis.

Home | What is HCV | Transmission | Future | Complications | Biopsy | Treatment | Lab | Nutrition | Patient | Links | Transplant | Webrings | guestbookbook | Awards | FAQ |